Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Durvalumab plus cisplatin–gemcitabine before surgery followed by adjuvant durvalumab may be feasible for muscle-invasive urothelial carcinoma

Advanced urothelial cancer patients who have received a PD-1 or PD-L1 inhibitor and are unable to have cisplatin may benefit from enfortumab vedotin therapy

Dose-intensified salvage radiotherapy offers no benefit over a conventional regimen for men with rising PSA after radical prostatectomy

SWOG 1500 trial findings point to cabozantinib for the treatment of metastatic papillary kidney cancer

Phase III trial indicates progression-free survival advantage for advanced renal cell carcinoma patients given lenvatinib plus pembrolizumab compared with sunitinib

[177Lu]Lu-PSMA-617 treatment offers a higher rate of PSA response than cabazitaxel for patients with metastatic castration-resistant prostate cancer

Oestradiol changes in male breast cancer patients undergoing hormone therapy mirror those found in premenopausal women receiving treatment

Metastatic pancreatic cancer patients do not gain a survival benefit from the use of ibrutinib alongside first-line chemotherapy